What is HC Wainwright's Estimate for GYRE Q3 Earnings?

Key Points

• HC Wainwright has issued a Q3 2025 earnings estimate for Gyre Therapeutics, projecting earnings per share of $0.07 and maintaining a "Buy" rating with a price target of $18.00.
• Gyre Therapeutics recently reported Q2 earnings of $0.02 per share, missing estimates, along with a revenue of $26.77 million, below the expected $30.80 million.
• Institutional investors have significantly increased their stakes in Gyre Therapeutics, with Bank of America and JPMorgan Chase boosting their holdings by 28.8% and 84.6%, respectively.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for Gyre Therapeutics in a research report issued on Tuesday, August 26th. HC Wainwright analyst M. Keller forecasts that the company will post earnings per share of $0.07 for the quarter. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. HC Wainwright also issued estimates for Gyre Therapeutics' Q4 2025 earnings at $0.06 EPS, FY2025 earnings at $0.17 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at ($0.09) EPS.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.01). The business had revenue of $26.77 million for the quarter, compared to analyst estimates of $30.80 million. Gyre Therapeutics had a return on equity of 7.67% and a net margin of 4.08%.

Gyre Therapeutics Price Performance

NASDAQ:GYRE traded down $0.54 on Thursday, hitting $7.74. 76,302 shares of the company's stock were exchanged, compared to its average volume of 89,665. The firm has a 50-day moving average price of $7.58 and a 200-day moving average price of $8.84. Gyre Therapeutics has a 52 week low of $6.11 and a 52 week high of $19.00. The company has a market cap of $745.44 million, a P/E ratio of 774.77 and a beta of 1.80.

Institutional Trading of Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN boosted its holdings in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company's stock valued at $49,000 after buying an additional 913 shares during the last quarter. Barclays PLC raised its position in Gyre Therapeutics by 13.5% during the fourth quarter. Barclays PLC now owns 10,543 shares of the company's stock worth $128,000 after acquiring an additional 1,255 shares in the last quarter. Bank of America Corp DE lifted its stake in Gyre Therapeutics by 28.8% in the second quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock valued at $46,000 after acquiring an additional 1,402 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Gyre Therapeutics by 15,083.3% in the 1st quarter. GAMMA Investing LLC now owns 1,822 shares of the company's stock valued at $140,000 after acquiring an additional 1,810 shares during the period. Finally, Bank of New York Mellon Corp grew its position in shares of Gyre Therapeutics by 18.7% in the 1st quarter. Bank of New York Mellon Corp now owns 16,492 shares of the company's stock valued at $127,000 after acquiring an additional 2,596 shares during the period. Institutional investors own 23.99% of the company's stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.